COV2-3025
An anti-RBD (SARS-CoV-2 Spike) human monoclonal antibody.
General information
COV2-3025 is a human monoclonal antibody identified in serum of a COVID-19 convalescent patient. It bound SARS-CoV-2 Spike RBD and neutralized the live virus in vitro (Zost et al., 2020a). The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect (Winkler et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Spike protein Animal model In vitro Antibody |
in vitro binding assay; Vero E6 cells; K18-hACE c57BL/6J mice; Syrian hamsters; SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 | 38.64 | The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect. |
Feb/12/2021 |
